anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Physical training programs are typically composed of activities directed to the development of different valences usually stimulated in the same session. When aerobic activities of long duration prior isokinetic strength exercises, isotonic, or explosive, deleterious effects seem to be induced on performance of these valences. These short and long-term changes in muscle strength and power would be directly associated with repetitive eccentric loads that characterize the endurance running. Gradual increases in the running slope were inversely associated with a proportional reduction in the eccentric loads, which in turn would result in less muscle damage to intra and extrafusal fibers. So, the change in the slope of the race would emerge as an optional way to neutralize the competitive effect on the power performance. The research consisted of five visits. At the initial visit was conducted familiarization to vertical drop jump, and immediately after, the determination of VO2max values and their associated speed (vVO2max). The second visit was a new familiarization for the vertical drop jump followed immediately determining the Time to exhaustion performance in vVO2max (100% of VO2Max). Two jumps were performed on each of the three selected heights (20, 30 and 40 cm) were used in the experimental sessions and control only the height associated with the highest performance. In subsequent visits (third to fifth), participants performed three maximum jumps before and about 10 min after the following conditions: high intensity Interval running a 10% gradient (C10%), 1% grade (C1%) and control condition (CON).
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA, from initial diagnosis, despite multimodal treatment approaches. Initial therapy consists of either surgical resection, external beam radiation or both. The role of adjuvant or concomitant chemotherapy in the initial therapy of GBM and AA has not, as yet, been clearly defined. Since most of these patients experience a recurrence after first-line therapy, improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. In August 2003, the U.S. Food and Drug Administration (FDA) granted orphan drug status for Erlotinib in patients with malignant glioma. Erlotinib (OSI-774) has been shown to be active in a range of tumors including GBM, AA and non small cell lung cancer. Because of the promising results in preliminary studies of Erlotinib and because of significant experience with the safety of the dosages proposed in this study, this study will offer a safe adjuvant treatment for patients with relapsing recurring glioblastoma or anaplastic astrocytoma. Therefore, this phase I/II clinical research trial will test the hypothesis that Erlotinib can be safely used up to a dose of 150 mg bid for 12 cycles to ultimately enhance survival of patients with relapsed/refractory GBM/AA with particular genetic alterations including EGFRvIII amplification and PTEN loss.
INTRODUCTION: Over the years, Dorsal Inlay Graft (DIG) urethroplasty has gained worldwide acceptance for primary hypospadias repair. However, its safety and effectiveness for revision surgery are yet to be proven.
OBJECTIVE: The aim of the study is to assess and compare complication rates and functional outcomes of DIG surgery in revision versus primary hypospadias repair.
MATERIAL AND METHODS: We carried out a retrospective analysis of data collected from 53 consecutive DIG urethroplasties performed by a single surgeon at our institution. Patients were stratified in two groups - primary repair and redo-urethroplasty. For each group, we recorded standard pre-operative characteristics, surgical technicalities, complication rates and uroflowmetry parameters.
RESULTS: Out of 53 DIG urethroplasties, 21 (39.6 %) where primary and 32 (60.4 %) were re-do. As expected, the two groups differed for median age at surgery: 20 months for primary and 68.5 months for revision surgery (p < 0.001). Additionally, all 21 (100 %) primary interventions were performed with a preputial graft, whereas among revision DIG urethroplasties only 2 (6.3 %) where preputial and 30 (93.8 %) were buccal (p < 0.001). Catheterization time (7 vs 8 days, p = 0.155) and postoperative complication rates (14.3 % vs 9.4 %, p = 0.581) were comparable between the primary and revision surgery group, respectively (all p > .05). Forty-two of the 53 patients underwent uroflowmetry during follow-up. Of these, 19 (63 %) patients presented with abnormal uroflowmetry and 11 (37 %) had equivocal parameters with no difference between the two groups.
DISCUSSION: Dorsal Inlay Graft urethroplasty has long been known to be safe and effective for primary hypospadias repair. On the other hand, data on dorsal inlay graft urethroplasty as a salvage surgery after primary hypospadias repair failure is scarce. Surprisingly, according to our findings, surgical outcomes and complication rates are comparable between primary and revision hypospadias cases. Additionally, our results in the redo group are absolutely encouraging if compared to those reported in the literature for the same subset of patients.
CONCLUSIONS: According to our findings, DIG urethroplasty is a safe and effective option to treat revision hypospadias repair.
AIMS: Valvular heart disease (VHD) is one of the leading causes of heart failure. Clinically significant VHD can induce different patterns of cardiac remodelling, and risk stratification is challenging in patients with various degrees of cardiac dysfunction. The study aimed to investigate the prognostic implications of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score in patients with VHD.
METHODS AND RESULTS: This study used data from the China Valvular Heart Disease (China-VHD) registry, which was a multicentre, prospective, observational cohort study for patients with significant (at least moderate) VHD. In total, 10 446 patients with moderate or greater VHD from the China-VHD study were included in the present analysis. The primary outcome of interest was all-cause mortality within 2 years. Among 10 446 patients with VHD, the mean age was 61.98 ± 13.47 years, and 5819 (55.7%) were male. During 2 years of follow-up, 895 (8.6%) patients died. The MAGGIC score was monotonically and independently associated with mortality in both total cohort [adjusted hazard ratio: 1.095, 95% confidence interval (CI): 1.084-1.107, P < 0.001] and most types of VHD (aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, mixed aortic stenosis and aortic regurgitation, and multiple VHD). The score was also an independent prognostic factor in patients with or without symptoms or preserved left ventricular ejection fraction (LVEF) and exhibited both satisfactory discrimination and calibration properties in predicting mortality. The prognostic value of MAGGIC score was robust in most quartiles of N-terminal pro-brain natriuretic peptide level, with no significant interaction observed (Pinteraction  = 0.498). Compared with the EuroSCORE II, the MAGGIC score achieved significantly better predictive performance in overall population [C index: 0.769 vs. 0.727; net reclassification improvement index (95% CI): 0.354 (0.313-0.396), P < 0.001; integrated discrimination improvement index (95% CI): 0.069 (0.052-0.085), P < 0.001] and in subgroups of patients divided by therapeutic strategy, LVEF, symptomatic status, stage of VHD, and aetiology of VHD.
CONCLUSIONS: The MAGGIC score is a reliable prognostic factor across the range of cardiac dysfunction in VHD and may assist in risk stratification and guide clinical decision-making.
To match for attention, the control condition will be a 10-week program that consists of weekly 60-75 minute group classes. In classes, instructors will provide information about general health topics through a variety of means such as slides and handouts. There will be an emphasis on group discussion of relevant topics; instructors do not just lecture. The core rationale for this course is that good physical health is important for good mental health. Instructors will provide information and encourage questions but avoid psychotherapeutic techniques or personalized goal-setting. Instructors will give participants readings to explore on their own.
PURPOSE:The titled composition having improved suppressing effects on body smell free from skin irritation in application to skin parts such as the armpit, feet or the crotch apt to give out an offensive smell, containing a polylysine as an active ingredient. CONSTITUTION:A skin deodorant composition containing a polylysine as an active ingredient. As the polylysine, alpha-polylysine wherein an amino group and a carboxyl group at the alpha position are condensed and epsilon-polylysine wherein an amino group and a carboxyl group at the epsilon position are condensed exist and the epsilon-polylysine is preferable as the skin deodorant composition. In use, the composition is made into a fine powder state and directly used or blended with a carrier or dissolved in a liquid and used as a liquid spray. The amount of the polylysine for once is 1-50mg based on 100cm<2>. The epsilon-polylysine is produced by cultivating a bacterium belonging to the genus Streptomyces under an aerobic condition.
Healthy aging results in cardiac structural and electrical remodeling that increase susceptibility to cardiovascular diseases. Relaxin has shown broad cardioprotective effects including anti-fibrotic, anti-arrhythmic and anti-inflammatory outcomes in multiple models. This paper focuses on the cardioprotective effects of Relaxin in a rat model of aging. Sustained atrial or ventricular fibrillation are readily induced in the hearts of aged but not young control animals. Treatment with Relaxin suppressed this arrhythmogenic response by increasing conduction velocity, decreasing fibrosis and promoting substantial cardiac remodeling. Relaxin treatment resulted in a significant increase in the levels of: Nav1.5, Cx43, βcatenin and Wnt1 in rat hearts. In isolated cardiomyocytes, Relaxin increased Nav1.5 expression. These effects were mimicked by CHIR 99021, a pharmacological activator of canonical Wnt signaling, but blocked by the canonical Wnt inhibitor Dickkopf1. Relaxin prevented TGF-β-dependent differentiation of cardiac fibroblasts into myofibroblasts while increasing the expression of Wnt1; the effects of Relaxin on cardiac fibroblast differentiation were blocked by Dickkopf1. RNASeq studies demonstrated reduced expression of pro-inflammatory cytokines and an increase in the expression of α- and β-globin in Relaxin-treated aged males. Relaxin reduces arrhythmogenicity in the hearts of aged rats by reduction of fibrosis and increased conduction velocity. These changes are accompanied by substantial remodeling of the cardiac tissue and appear to be mediated by increased canonical Wnt signaling. Relaxin also exerts significant anti-inflammatory and anti-oxidant effects in the hearts of aged rodents. The mechanisms by which Relaxin increases the expression of Wnt ligands, promotes Wnt signaling and reprograms gene expression remain to be determined.
BACKGROUND: Docosahexaenoic acid (DHA) controls the biophysical organization of plasma membrane sphingolipid/cholesterol-enriched lipid rafts to exert anti-inflammatory effects, particularly in lymphocytes. However, the impact of DHA on the spatial arrangement of alveolar macrophage lipid rafts and inflammation is unknown.
OBJECTIVES: The primary objective was to determine how DHA controls lipid raft organization and function of alveolar macrophages. As proof-of-concept, we also investigated DHA's anti-inflammatory effects on select pulmonary inflammatory markers with a murine influenza model.
METHODS: MH-S cells, an alveolar macrophage line, were treated with 50 μM DHA or vehicle control and were used to study plasma membrane molecular organization with fluorescence-based methods. Biomimetic membranes and coarse grain molecular dynamic (MD) simulations were employed to investigate how DHA mechanistically controls lipid raft size. qRT-PCR, mass spectrometry, and ELISAs were used to quantify downstream inflammatory signaling transcripts, oxylipins, and cytokines, respectively. Lungs from DHA-fed influenza-infected mice were analyzed for specific inflammatory markers.
RESULTS: DHA increased the size of lipid rafts while decreasing the molecular packing of the MH-S plasma membrane. Adding a DHA-containing phospholipid to a biomimetic lipid raft-containing membrane led to condensing, which was reversed with the removal of cholesterol. MD simulations revealed DHA nucleated lipid rafts by driving cholesterol and sphingomyelin into rafts. Downstream of the plasma membrane, DHA lowered the concentration of select inflammatory transcripts, oxylipins, and IL-6 secretion. DHA lowered pulmonary Il6 and Tnf-α mRNA expression and increased anti-inflammatory oxylipins of influenza-infected mice.
CONCLUSIONS: The data suggest a model in which the localization of DHA acyl chains to nonrafts is driving sphingomyelin and cholesterol molecules into larger lipid rafts, which may serve as a trigger to impede signaling and lower inflammation. These findings also identify alveolar macrophages as a target of DHA and underscore the anti-inflammatory properties of DHA for lung inflammation.
The eligible patients randomly into training cohort and validation cohort. The univariate logistics regression analyses were performed to determine the independent risk characteristics in the training cohort of the presence of in-hospital all-cause death. Odds Ratios (ORs) and 95% confidence intervals (CIs) of these variables were estimated to quantify the strength of these associations. All variables that showed a univariate relationship with in-hospital mortality or that were considered clinically relevant were candidates for stepwise multivariate analysis in the training cohort. A nomogram model, producing by using the rms package, was formulated based on the results of independent risk factors in multivariate logistic regression. Based on the nomogram model, the total scores and prediction of in-hospital mortality risk of each patient were added by each eligible variable and then were converted to predicted probabilities both in the training cohort and validation cohort.

To evaluated the model for the prediction value of in-hospital mortality, firstly, the investigators calculated the calibration of the model was measured by calibration with 1000 bootstrap samples to decrease the overfit bias. Model fitting was assessed using the Hosmer-Lemeshow test to evaluate the goodness of fit. Secondly, the Harrell concordance index (C index) and receiver operating characteristic curve (ROC curve) to evaluate the predictive performance and discrimination of the nomogram. The ROC curve analysis was used to calculate the optimal cutoff values that were determined by maximizing the Youden index. Third, the clinical effectiveness of the resulting model was evaluated by decision curve analysis (DCA), which was a method for evaluating alternative diagnostic or prognostic tools that had advantages over others\[16\]. The increase in the discriminative value of MEWS and the resulting model for mortality was assessed by the net reclassification index (NRI).
Anemia is sometimes seen in patients receiving NSAIDs, including NALFON tablets. This may be due to fluid retention, occult or gross GI blood loss or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including NALFON tablets, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving NALFON tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.
In addition to being a popular team activity, cricket requires complex abilities that are developed through time, particularly in bowling. The possibility of shoulder injuries resulting from imbalances between the agonist and antagonist muscle groups is one of the main worries for bowlers. The Ballistic Six program aims to improve the rotator cuff muscles' strength, power, proprioception, kinesthesia, and endurance by using functional exercises that mimic the motions and pressures involved in the overhead throwing action. The program's goal is to minimize the stretch shortening cycle's amortization phase and maximize the stretch reflex by combining plyometric training in a ballistic, high-velocity way. Furthermore, training with blood flow restriction (BFR) has demonstrated encouraging outcomes in enhancing muscle mass and power. Lean mass, isometric strength, and muscular endurance in the shoulder and arm are enhanced by BFR, which produces muscle hypoxia while limiting venous return by placing a tourniquet to the arm during intra-set rests. Medium-pace cricket bowlers can benefit from these training techniques in terms of both overall performance and injury prevention.

To maintain fairness in this Randomized Controlled Trial, volunteers will be chosen at random. The 18-25-year-old cricket players will be split into two groups: an experimental group and a control group. Ballistic Six upper extremity plyometric training will be administered to the control group, while Ballistic Six training combined with blood flow restriction treatment will be administered to the experimental group. The course of therapy will last for eight weeks, with monthly progress reports. There will be three weekly recovery sessions, each lasting 20 to 30 minutes. Tests such as the Kerlan Jobe Orthopedic Clinic (KJOC) Shoulder and Elbow Score, the Closed Kinetic Chain Upper Extremity Stability Test, and the Seated Medicine Ball Throw Test will be used to assess patients both at the start and finish of their therapy.
Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
Compounds are made by reacting adenylic acid or sodium adenylate with one or more components of the Vitamin B complex (including choline), or their acid salts.  If free adenylic acid is reacted with an acid salt sodium hydroxide is added subsequently.  The reaction takes place in aqueous solution or suspension, preferably with heat, and the product may be obtained solid by evaporation or addition of an organic solvent in which it is insoluble.  The inorganic sodium salt may if desired be separated.  The reactants are preferably used in stoichiometric proportions.  Examples show the preparation of the following: (1) di-nicotinamide adenylate; (2) thiamine adenylate; (3) pyridoxin adenylate; (3) mono and diadenylates of riboflavin; (4) choline adenylate.  The process is applicable to both yeast and muscle adenylic acids.  The Specification as open to inspection under Sect. 91 refers to the use of other adenylates, viz. those of potassium, lithium, magnesium, zinc, manganese, iron, copper, cobalt and calcium.  It also includes the subject-matter of Specification 698,864, and also describes products similar to those of that Specification but obtained from members of the Vitamin B series and amino-acids without adenylic acid.  This subject-matter does not appear in the Specification as accepted.ALSO:Medicinal preparations comprise adenylic acid or sodium adenylate with one or more components of the vitamin B complex (including choline) or their acid salts.  The materials may be mixed as a powder to be taken with water, or as tablets or capsules.  Alternatively they may be reacted together to give a product which is probably a salt.  When free adenylic acid is used with an acid salt, sodium hydroxide is added so that the pH may be suitable for injection.  The inorganic sodium salt may be removed if desired.  The reactants are preferably used in stoichiometrical proportions.  Suitable products are thiamine adenylate, di-nicotin-amide adenylate, pyridoxin adenylate, riboflavin mono- and di-adenylate and choline adenylate.  The process is applicable to both yeast and muscle adenylic acids.  The Specification as open to inspection under Sect. 91 refers to the use of other adenylates, viz., those of potassium, lithium, manganese, zinc, magnesium, iron, copper, cobalt and calcium.  It also includes the subject-matter of Specification 698,864, and also describes products similar to those of that Specification but containing members of the vitamin B series and amino-acids without adenylic acid.  This subject-matter does not appear in the Specification as accepted.
Methods, systems, and apparatus, including computer programs encoded on computer storage media for determining a color pigment mixing recommendation based on a sensor reading of a person's skin. One or more color value sets of a person's skin are determined. The one or more color value sets are evaluated. A color pigment mixing recommendation is generated. The color pigment mixing recommendation including one or more color pigments and an amount of the color pigments to be mixed. The color pigment mixing recommendation is displayed, via a user interface of a client device, the color pigment mixing recommendation.
Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.
The study is a prospective, multi-center, single arm open-label clinical study involving up to 5 centers and a minimum of 20 subjects. Up to 50 subjects may be enrolled in this study. The first 3 post-dilatation procedures for each investigator will be considered roll-ins and not included in the main study analyses. Subjects will exit the study at hospital discharge or 7 days post treatment, whichever comes first. The expected duration of the clinical investigation is approximately 6 months.

Subjects implanted with the CoreValve or other commercially available self-expanding TAVI and with the use of the V8 as a postdilatation balloon may be enrolled in this study. The subject will exit the study after the predischarge ECHO where the Paravalvular Leak (PVL) measurements are taken or resolution of a V8 related AE (if applicable).
Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
1. Technical Result Cheapening of the process for determination of individual’s immune status.         2. Essence Trophoblastic beta-1 glycoprotein is used for determining the suppressor cell component of the immune status of an individual. To effect this a suspension of mononuclear cells is obtained from a peripheral blood, divided into two equal fractions, one fraction of mononuclear cells is cultivated without a suppressor cell activator, and the second fraction - with beta-1 glycoprotein,  the mononuclear cells are washed to remove the culture medium and proliferation is blocked. To obtain a test culture to each mononuclear cells fraction a freshly separated mononuclear cells taken from a healthy donor and stimulated by the action of phytohaemagglutinin is added. Then culturing of the mononuclear cells, subsequent assessment of proliferation and determination of the suppression value in relation to the proliferation levels in the test cultures takes place.     3. Field of Application Medicine.